Spectrum makes deeper commitment to Zevalin

non-hodgkin-throat-scan.jpg

Spectrum Pharmaceuticals has announced that it intends to acquire the international rights to Zevalin from Bayer Healthcare at a cost of $24.7 million up front, with royalty payments on sales to follow.

Spectrum currently controls the rights to Zevalin in the United States and several other countries, and it markets the drug regimen as a treatment for certain non-Hodgkin's lymphomas.

Spectrum bought Zevalin from Cell Therapeutics Inc. in April 2008. According to the company, sales have tripled in that time.

Source: CBS News

LymphomaInfo Social